Michael Burry, the man who famously shorted the housing market before the 2008 crash, has revealed his latest moves. According to Scion Asset Management's most recent 13F filing, he's initiated new positions in Pfizer (PFE), Halliburton (HAL), Molina Healthcare (MOH), and Lululemon Athletica (LULU). The immediate question: is this a sign of something brewing, or just portfolio diversification?
Let's break down the picks. Pfizer, Halliburton, Molina, and Lululemon. Seemingly disparate, right? At first glance, there's no obvious thematic link. One's a pharmaceutical giant, another an oilfield services company, the third a managed healthcare provider, and the last an athletic apparel retailer. This isn't like his concentrated bets against subprime mortgages. So, what's the angle?
The market often reacts to Burry's moves, treating them as signals. But before we jump on the bandwagon, it's crucial to remember a few things. 13F filings are backward-looking. They reflect positions taken last quarter. By the time we see them, Burry could have already exited or significantly altered his holdings. (Information arbitrage, in this game, has a very short shelf life). Also, the filings don't tell us why he made these moves. We're left to speculate, which is a dangerous game.
Here's where my analysis gets interesting. The filing shows these new positions alongside existing ones. We need to look at the relative size of these bets. Are they conviction plays, or simply minor adjustments to a larger portfolio? Often, these filings can be misleading because the media reports them out of context.
I've looked at hundreds of these filings, and the thing that stands out here is how unremarkable this is. It's a fairly balanced portfolio, not a screaming "the sky is falling" trade. Which, frankly, is a bit of a letdown.
This is where a methodological critique is needed. 13F filings only show long positions. They don't reveal short positions or derivative strategies. It's entirely possible that Burry is using these long positions as hedges against other, undisclosed bets. We're only seeing half the picture.
So, what can we realistically conclude? The truth is, without more information, it's tough to say definitively. We can speculate about potential catalysts for each company. Pfizer might be undervalued after recent vaccine-related declines. Halliburton could be a play on rising energy prices. Molina might benefit from changes in healthcare policy. Lululemon could be a bet on continued consumer spending. Michael Burry adds bullish bets on Pfizer, Halliburton, Molina, and Lululemon (PFE:NYSE)
But these are just narratives. The data, in this case, is incomplete. We're missing crucial pieces of the puzzle. Remember that correlation isn't causation. Just because Burry bought these stocks doesn't mean they're guaranteed to rise.
I'm not seeing a clear, actionable signal here. It's more like white noise. My advice? Don't blindly follow any investor, no matter how legendary. Do your own homework.
beta technologies: what we know
2025-11-05
